JP2019505598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505598A5 JP2019505598A5 JP2018563402A JP2018563402A JP2019505598A5 JP 2019505598 A5 JP2019505598 A5 JP 2019505598A5 JP 2018563402 A JP2018563402 A JP 2018563402A JP 2018563402 A JP2018563402 A JP 2018563402A JP 2019505598 A5 JP2019505598 A5 JP 2019505598A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- day
- level
- patient
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 112
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 101
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 101
- 101700026522 SMAD7 Proteins 0.000 claims description 95
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims 5
- 229940123231 SMAD7 inhibitor Drugs 0.000 claims 4
- 210000001842 enterocyte Anatomy 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 208
- 102000049873 Smad7 Human genes 0.000 description 90
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 69
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 69
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 69
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000652166 Homo sapiens Mothers against decapentaplegic homolog 7 Proteins 0.000 description 6
- 102000044356 human SMAD7 Human genes 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 238000010276 construction Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical class Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298988P | 2016-02-23 | 2016-02-23 | |
| US62/298,988 | 2016-02-23 | ||
| PCT/US2017/019094 WO2017147276A1 (en) | 2016-02-23 | 2017-02-23 | Methods of treating intestinal fibrosis using smad7 inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019505598A JP2019505598A (ja) | 2019-02-28 |
| JP2019505598A5 true JP2019505598A5 (https=) | 2020-04-16 |
Family
ID=59686543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563402A Pending JP2019505598A (ja) | 2016-02-23 | 2017-02-23 | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11162097B2 (https=) |
| EP (1) | EP3420082A4 (https=) |
| JP (1) | JP2019505598A (https=) |
| WO (1) | WO2017147276A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505598A (ja) | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| CN108753791B (zh) * | 2018-07-01 | 2020-10-13 | 中国农业科学院植物保护研究所 | 绿盲蝽decapentaplegic基因及其RNAi在害虫防控中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| PT1456380E (pt) | 2001-11-02 | 2012-07-23 | Giuliani Int Ltd | Inibidores smad7 para o tratamento de doenças do snc |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| ES2617200T3 (es) | 2011-09-15 | 2017-06-15 | Nogra Pharma Limited | Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 |
| CA2864059C (en) * | 2012-02-09 | 2020-04-28 | Nogra Pharma Limited | Methods of treating fibrosis |
| US10081809B2 (en) | 2012-04-18 | 2018-09-25 | University Of Miami | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US9078918B2 (en) * | 2012-05-08 | 2015-07-14 | Northwestern University | Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA) |
| WO2014111584A1 (en) * | 2013-01-18 | 2014-07-24 | Genfit | Methods of treatment of fibrosis and cancers |
| RU2674147C2 (ru) | 2013-03-15 | 2018-12-05 | Ногра Фарма Лимитед | Способы лечения колоректального рака |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| AU2015257589A1 (en) | 2014-05-09 | 2016-11-24 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| WO2016059239A1 (en) | 2014-10-17 | 2016-04-21 | Nogra Pharma Limited | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
| WO2015011694A2 (en) | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues of smad7 antisense oligonucleotides |
| MA41271A (fr) | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| EP3355896A2 (en) * | 2015-09-30 | 2018-08-08 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| MX2018003699A (es) | 2015-09-30 | 2018-08-01 | Celgene Alpine Invest Company Ii Llc | Moduladores de tlr y metodos de uso. |
| PT3380615T (pt) * | 2015-11-25 | 2021-04-01 | Nogra Pharma Ltd | Oligonucleótidos antissentido il-34 e métodos de utilização dos mesmos |
| JP2019505598A (ja) | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| US20210207143A1 (en) | 2016-02-24 | 2021-07-08 | Nogra Pharma Limited | Methods of Treating Celiac Disease Using SMAD7 Inhibition |
| US20200237801A1 (en) | 2016-05-12 | 2020-07-30 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| JP2020503327A (ja) | 2016-12-30 | 2020-01-30 | ノグラ ファーマ リミテッド | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法 |
| EP3658155A4 (en) | 2017-07-28 | 2021-06-30 | Nogra Pharma Limited | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDIC COMPOUNDS |
-
2017
- 2017-02-23 JP JP2018563402A patent/JP2019505598A/ja active Pending
- 2017-02-23 WO PCT/US2017/019094 patent/WO2017147276A1/en not_active Ceased
- 2017-02-23 EP EP17757196.5A patent/EP3420082A4/en not_active Withdrawn
- 2017-02-23 US US16/079,059 patent/US11162097B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hanania | Targeting airway inflammation in asthma: current and future therapies | |
| JP2017537973A5 (https=) | ||
| Hammers et al. | Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle | |
| JP2018531936A5 (https=) | ||
| JP2019507755A5 (https=) | ||
| US20180180630A1 (en) | Methods for treating inflammatory bowel disease | |
| WO2019191464A1 (en) | Methods of treating ulcerative colitis | |
| CN105358150A (zh) | 用于心脏病的bet抑制疗法 | |
| Donkervoort et al. | Mosaicism for dominant collagen 6 mutations as a cause for intrafamilial phenotypic variability | |
| KR20170031245A (ko) | 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물 | |
| CA2962944A1 (en) | Use of reslizumab to treat moderate to severe eosinophilic asthma | |
| JP2025143437A (ja) | ヒト対象者における心不全の治療 | |
| US20190112608A1 (en) | Methods of using smad7 antisense oligonucleotides | |
| JP2019519544A5 (https=) | ||
| JPWO2020234834A5 (https=) | ||
| JP2019505598A5 (https=) | ||
| EP3380615B1 (en) | Il-34 antisense oligonucleotides and methods of using same | |
| Lattuada et al. | The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes | |
| CN111630168B (zh) | 治疗心力衰竭的改良化合物 | |
| WO2013088853A1 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| US20100105762A1 (en) | Therapeutic agent for periodontal disease and alveolar bone loss due to surgery | |
| Kameda et al. | Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients | |
| US20170136089A1 (en) | Compositions and methods of regulating bone resorption | |
| RU2794975C2 (ru) | Усовершенствованное соединение для лечения сердечной недостаточности | |
| Strong | Medical Management of Crohn’s Disease |